COAG

Hemab Therapeutics is a biotech company developing treatments for rare bleeding disorders. Their main drug candidate, HMB-001, is an antibody designed to prevent bleeding episodes in patients with Glanzmann thrombasthenia and Factor VII deficiency. Another drug candidate, HMB-002, is being tested as a preventive treatment for Von Willebrand disease that patients could inject at home. The company is still in early-stage testing and was founded in 2020.